drugset / Trial / NCT06268327
Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy
RandomizedParallel-groupOpen-labelTreatment
Summary
In our study; investigator aim To show efficacy and toxicity of Adjuvant cisplatin and gemcitabine in triple-negative breast cancer patients with non pathologically complete response after neoadjuvant chemotherapy To compare outcome of adjuvant cisplatin and gemcitabine versus capecitabine
Timeline
- Start
- 2024-04-30
- Primary completion
- 2025-10-30
- Completion
- 2026-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Capecitabine | Small molecule | 1250 mg/m2 | — |
| Subject | Cisplatin | Other / unclassified | 70 mg/m2 | — |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |